All
An Rx for the System: Gaining Access to Investigational Drugs
February 26th 2015Expanded access programs are run in conjunction with late-stage clinical trials so that promising investigational drugs can get into the hands of patients who stand a good chance of benefiting from them, and who have exhausted their other treatment options, including clinical trials.
Men with Testicular Cancer More Likely to Develop Prostate Cancer
February 24th 2015A new study has shown that men with a history of testicular cancer have a higher incidence of developing prostate cancer, including intermediate or high-risk prostate cancer, compared with those without a history of testicular cancer.
FDA Approves Farydak for Multiple Myeloma
February 24th 2015The FDA has approved Farydak (panobinostat) in combination with Velcade (bortezomib) and dexamethasone for patients with multiple myeloma who receive prior treatment with Velcade and an immunomodulatory (IMiD) agent, based on results of the PANORAMA-1 trial.
Chemobrain—It's Real, It's Complex, and the Science Is Still Evolving
February 17th 2015Talk with almost any cancer survivor, and he or she is likely to bring up the topic of "chemobrain," that fuzzy, murky state that patients blame for impaired memory. A review of the research shows how we're focusing on the problem.
Oncology Society Endorses Guidelines for Prostate Cancer Survivor Care
February 16th 2015ASCO has endorsed new prostate cancer survivorship care guidelines from the American Cancer Society that provide a structure to help prostate cancer patients with localized disease to receive high quality care from specialists and primary care physicians.